Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine adjunct to sufentanil for analgesia in mechanically ventilated non-surgical ICU patients
ChiCTR2200058933Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of esketamine and sufentanil in critical illness (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Mean hourly sufentanil consumption during the treatment period. Started Apr 2022; status: recruiting.
02
Drugs
esketaminesufentanil
03
Conditions
critical illness
Beyond the preview
Go deeper on ChiCTR2200058933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058933.